Form 4: Edwards Lifesciences Exec Reports Stock Transactions

Donald E. Bobo Jr., VP of Strategy and Corporate Development at Edwards Lifesciences, reported transactions involving common stock and performance rights.

Summary

• Donald E. Bobo Jr., VP of Strategy and Corporate Development at Edwards Lifesciences Corp., reported transactions on May 11, 2026.
• He acquired 13,457 shares of common stock with a transaction code 'M' (likely a grant or award) and a price of $0.
• He also disposed of 7,469 shares of common stock at a price of $79.96 per share.
• Following these transactions, Bobo beneficially owns 40,235.2532 shares directly and an additional 38,969.5756 shares indirectly.
• His indirect holdings include shares within a 401(k) plan and shares held by a trust.
• The filing also notes performance rights related to a restricted stock unit grant with performance-based vesting requirements over a three-year period.
• The Compensation and Governance Committee determined that 167.70% of the target shares vested as of May 11, 2026.
• These performance rights expire on May 10, 2030.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive due to the significant vesting of performance-based awards, indicating strong performance against targets, balanced by the disposal of some shares.

Positives

• Vesting of performance rights indicates achievement of performance targets, with 167.70% of target shares vesting.
• Acquisition of 13,457 shares of common stock at $0 cost suggests an award or grant from the company.
• The reporting person continues to hold a significant number of shares, both directly and indirectly, indicating continued investment in the company.

Negatives

• Disposal of 7,469 shares of common stock at $79.96 per share could indicate a reduction in direct holdings, though the reason is not specified.

Risks

• The performance rights have an expiration date of May 10, 2030, implying a time-bound opportunity for value realization.
• The filing does not provide details on the specific performance metrics that led to the vesting of the performance rights, which could be a point of interest for investors.

Future Outlook

The performance rights granted on May 11, 2023, have a vesting period over three years and expire on May 10, 2030. The actual number of shares vested as of May 11, 2026, indicates a positive outcome regarding performance targets.

Management Comments

• On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the medical technology sector, providing transparency on executive compensation and potential shifts in insider holdings.

Stakeholder Impact

• Shareholders: The vesting of performance rights at a high percentage may be viewed positively, suggesting effective management and achievement of company goals. The disposal of shares by an executive could be interpreted in various ways, but without further context, it's neutral.
• Employees: The success indicated by performance vesting could reflect positively on overall company performance and employee contributions.
• Management: The filing details executive compensation tied to performance, a common governance practice.

Next Steps

• The performance rights expire on May 10, 2030.
• Further transactions by the reporting person will be disclosed in subsequent Form 4 filings.

Key Dates

Keywords

Form 4, SEC Filing, Edwards Lifesciences, EW, Stock Transaction, Beneficial Ownership, Donald E. Bobo Jr., Performance Rights, Restricted Stock Units, Insider Trading, Executive Compensation